Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 435-442

  Oh, Eun Taex ^a   Park, Moon Taek ^a   Choi, Bo Hwa ^a   Ro, Seonggu ^b   Choi, Eun Kyung ^c   Jeong, Seong Yun ^c   Park, Heon Joo ^a  

^a Inha University School of Medicine   (South Korea)

^b CrystalGenomics Inc   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

Acetylation; CG200745; Histone deacetylase inhibitor; p53

Indexed keywords

CG 200745; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; N1 [3 (DIMETHYLAMINO)PROPYL] N8 HYDROXY 2 [(NAPHTHALENE 1 LOXY)METHYL]OCT 2 ENEDIAMIDE; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE; HISTONE DEACETYLASE; HYDROXAMIC ACID; LYSINE; MDM2 PROTEIN, HUMAN; N1 (3 (DIMETHYLAMINO)PROPYL) N8 HYDROXY 2 ((NAPHTHALENE 1 LOXY)METHYL)OCT 2 ENEDIAMIDE; N1-(3-(DIMETHYLAMINO)PROPYL)-N8-HYDROXY-2-((NAPHTHALENE-1-LOXY)METHYL)OCT-2-ENEDIAMIDE; NAPHTHALENE DERIVATIVE; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL DEATH; CLONOGENIC ASSAY; CLONOGENIC CELL DEATH; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; TRANSACTIVATION; ACETYLATION; COLORECTAL TUMOR; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HALF LIFE TIME; MALE; METABOLISM; MUTATION; PATHOLOGY; PROSTATE TUMOR; PROTEIN STABILITY; REPORTER GENE; TIME; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ACETYLATION; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HALF-LIFE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; LYSINE; MALE; MUTATION; NAPHTHALENES; PROSTATIC NEOPLASMS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862265924     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9568-2     Document Type: Article

References (33)

1. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51
2. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21-33
3. Fraga MF, Ballestar E, Villar-Garea A (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391-400
4. Wade PA (2001) Transcriptional control at regulatory checkpoint by histone deacetylase: molecular connections between cancer and chromatin. Hum Mol Genet 10:693-698
5. Kelly WK, Richon VM, O'Connor O et al (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588
6. Kelly WK, O'Connor OA, Marks PA (2002) Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Inv Drug 12:1695-1713
7. Yoshida M, Kijima M, Akita M et al (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174-17179
8. Kijima M, Yoshida M, Sugita K et al (1993) Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268:22429-22435
9. Ruefli AA, Ausserlechner MJ, Bernhard D et al (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98:10833-10838
10. Giuliano M, Lauricella M, Calvaruso G et al (1999) The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 59:5586-5595
11. Cao XX, Mohuiddin I, Ece F et al (2001) Histone deacetylase inhibitor down-regulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25:562-568
12. Goh M, Chen F, Paulsen MT et al (2001) Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia 3:331-338
13. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074-1080
14. Maeda T, Nagaoka Y, Kawai Y et al (2005) Inhibitory effects of cancer cell proliferation by novel histone deacetylase inhibitors involves p21/WAF1 induction and G2/M arrest. Biol Pharm Bull 28:849-853
15. Laurenzi VD, Roy S, Packman K et al (2005) Histone deacetylase inhibitors differentially stabilize acetylated p53 and induces cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12:482-491
16. Munshi A, Tanaka T, Hobbs ML et al (2006) Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5:1967-1974
17. Zhang K, Dent SY (2005) Histone modifying enzymes and cancer: going beyond histones. J Cell Biochem 96:1137-1148
18. Kim IA, Shin JH, Kim IH et al (2006) Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 12:940-949
19. Barlev NA, Liu L, Chehab NH et al (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8:1243-1254
20. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310
21. Lakin ND, Jackson SP (1999) Regulation of p53 in response to DNA damage. Oncogene 18:7644-7655
22. Zhao Y, Lu S, Wu L et al (2006) Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26:2782-2790
23. Ito A, Lai CH, Zhao X et al (2001) P300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20:1331-1340
24. Sakaguchi K, Herrera JE, Saito S et al (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831-2841
25. Liu L, Scolnick DM, Trievel RC et al (1999) p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19:1202-1209
26. Prives C, Manley JL (2001) Why is p53 acetylated? Cell 107:815-818
27. Terui T, Murakami K, Takimoto R et al (2003) Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase. Inhibitors Cancer Res 63:8948-8954
28. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981-989
29. Luo J, Su F, Chen D, Shiloh A et al (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408:377-381
30. Roy S, Tenniswood M (2007) Site-specific acetylation of p53 directs selective transcription complex assembly. J Biol Chem 282:4765-4771
31. Szak ST, Mays D, Pietenpol JA (2001) Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 21:3375-3386
32. Lee CH, Jung HJ, Kim JH et al. inventors; Crystal Genomics. Naphthalenyloxypropenyl detivatives having inhibitor activity against histone deacetylase and pharmaceutical composition comprising the same. World patent WO/2008/054154. 2008 May 8
33. Oh ET, Byun MS, Lee HM et al (2010) Aurora-A contributes to radioresistance by increasing NF-κB DNA binding. Radiat Res 174:265-273